Reduced Cardiovascular Risk Score Following Cataract Phacoemulsification Surgery

Published 2022 - 40th Congress of the ESCRS

Reference: PPE28.05 | Type: ESONT - Abstract | DOI: 10.82333/2g32-c836

Authors: Maria João Matias* ¹ , Pedro Alves Peixoto ² , Vítor Miranda ¹ , Catarina Pestana Aguiar ¹ , João Ambrósio ¹ , António Rocha ¹ , João Chibante-Pedro ¹

¹Centro Hospitalar de Entre o Douro e Vouga,Santa Maria da Feira,Portugal, ²Centro de Medicina de Reabilitação da Região Centro - Rovisco Pais,Tocha,Portugal

Purpose

Evaluate the cardiovascular risk (CV risk) change following bilateral phacoemulsification cataract surgery.

Setting/Venue

Centro Hospitalar de Entre o Douro e Vouga (CHEDV), Santa Maria da Feira, Portugal

Methods

We randomly selected 112 patients who underwent uncomplicated bilateral cataract surgery at CHEDV, without other known ophthalmological pathology,between 2018 and 2019. Their records of comorbidities, lipid profile and blood pressure were available before and up to 6 months following surgery. We also subdivided our patient cohort in 2 different groups: no to mild visual impairment (group 1) and moderate to severe visual impairment (group 2). We compared the evolution of the before mentioned variables, in our patient cohort and between subgroups, before and after surgery.

Results

Phacoemulsification cataract surgery resulted in markedly improved visual acuity (VA) regardless of baseline VA. Notably, following surgery our patient cohort showed improved lipidic profile and arterial blood pressure, translating an improved CV risk score within 6 months of cataract surgery. Of note, these improvements were mostly present in group 2 of patients, where baseline VA and incidence of dyslipidemia were worse.

Conclusions

Our results suggest that phacoemulsification cataract surgery may be an important tool in addressing CV risk.